Walleye Capital
CLDX icon

Walleye Capital’s Celldex Therapeutics CLDX Stock Holding History

Walleye Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,147
Closed -$258K – 4781
2026
Q1 		$258K Buy
+8,147
New +$222K ﹤0.01% 3167
2025
Q2 		– Sell
-93,327
Closed -$1.69M – 4561
2025
Q1 		$1.69M Buy
+93,327
New +$2.09M 0.01% 1540
2024
Q3 		– Sell
-50,183
Closed -$1.86M – 5361
2024
Q2 		$1.86M Buy
50,183
+49,147
+4,744% +$1.85M ﹤0.01% 2181
2024
Q1 		$43.5K Sell
1,036
-168,232
-99% -$6.91M ﹤0.01% 4729
2023
Q4 		$6.71M Buy
169,268
+10,275
+6% +$302K 0.01% 920
2023
Q3 		$4.38M Buy
158,993
+37,741
+31% +$1.18M 0.01% 1127
2023
Q2 		$4.11M Buy
121,252
+51,436
+74% +$1.73M 0.01% 858
2023
Q1 		$2.51M Sell
69,816
-15,456
-18% -$667K 0.04% 600
2022
Q4 		$3.8M Sell
85,272
-86,630
-50% -$3.09M 0.07% 334
2022
Q3 		$4.83M Buy
+171,902
New +$5.27M 0.09% 239
2022
Q2 		– Sell
-37,381
Closed -$1.27M – 2403
2022
Q1 		$1.27M Buy
37,381
+23,154
+163% +$740K 0.03% 522
2021
Q4 		$550K Buy
+14,227
New +$620K 0.02% 929

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's CLDX Position: Q2 2026 in Review

Walleye Capital sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 8,147 shares — an estimated $258K sold.

Walleye Capital first reported a position in CLDX in Q4 2021 and held it in 12 quarters. The position peaked at $6.71M in Q4 2023. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Walleye Capital reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 8,147 Celldex Therapeutics shares in Q2 2026, an estimated $258K.
  • Walleye Capital first reported a position in Celldex Therapeutics in Q4 2021 and held it in 12 quarters.
  • Walleye Capital's Celldex Therapeutics position peaked at $6.71M in Q4 2023.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.